From Seekingalpha · Eric Cottrell · · 30s
Immuneering Shares Hold Amid Survival Data
Immuneering's pancreatic cancer drug shows 17.3-month survival but cash burn risks limit stock upside.
In brief
Immuneering's pancreatic cancer drug shows 17.3-month survival but cash burn risks limit stock upside. Immuneering's pancreatic cancer treatment shows 17.3-month survival in early trials but significant cash burn could prevent stock buy rating. Originally reported by Seekingalpha.
Early Clinical Data
Immuneering's pancreatic cancer drug shows 17.3-month median survival in early trials.
Cash Burn Concerns
Company has $182.7M liquidity with annual cash outflows near $70M.
Investment Rating
Analyst maintains 'Hold' rating due to valuation risks and cash buffer concerns.
What matters most
Immuneering's pancreatic cancer treatment shows 17.3-month survival in early trials but significant cash burn could prevent stock buy rating.
